Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.210 -0.040 (-0.94%)
Streaming Delayed Price Updated: 3:36 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
A New Oral Therapy for Psoriasis Could Be Coming Soon ↗
Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice... 
Via Benzinga
News headline image
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
News headline image
CAN-FITE ISSUES LETTER TO SHAREHOLDERS ↗
Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,... 
Via Benzinga
News headline image
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO ↗
Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:... 
Via Benzinga
News headline image
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference ↗
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs... 
Via Benzinga
News headline image
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Issues Letter to Shareholders
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS ↗
Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a... 
Via Benzinga
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... 
Via Benzinga
News headline image
26 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... 
Via Benzinga
News headline image
CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today ↗
Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around? 
Via InvestorPlace
News headline image
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
26 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has... 
Via Benzinga
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
News headline image
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump ↗
Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the... 
Via Benzinga
News headline image
RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal ↗
Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill. 
Via InvestorPlace
News headline image
CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today ↗
Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. 
Via InvestorPlace
News headline image
38 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
News headline image
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug ↗
Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
News headline image
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022 ↗
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week... 
Via Benzinga
News headline image
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.